A Bioluminescence Reporter Assay for Retinoic Acid Control of Translation of the GluR1 Subunit of the AMPA Glutamate Receptor

Thabat Khatib1 · Andrew Whiting2 · David R. Chisholm2 · Christopher Redfern3 · Berndt Müller1 · Peter McCaffery1

Received: 5 November 2018 / Accepted: 20 March 2019 / Published online: 10 April 2019
© The Author(s) 2019

Abstract
Retinoic acid (RA) regulates numerous aspects of central nervous system function through modulation of gene transcription via retinoic acid receptors (RARs). However, RA has important roles independent of gene transcription (non-genomic actions) and in the brain a crucial regulator of homeostatic plasticity is RAR control of glutamate receptor subunit 1 (GluR1) translation. An assay to quantify RAR regulation of GluR1 translation would be beneficial both to study the molecular components regulating this system and screen drugs that influence this critical mechanism for learning and memory in the brain. A bioluminescence reporter assay was developed that expresses firefly luciferase under the control of the GluR1 5′ untranslated region bound by RAR. This assay was introduced into SH-SY5Y cells and used to demonstrate the role of RARα in RA regulation of GluR1 translation. A screen of synthetic RAR and RXR ligands indicated that only a subset of these ligands activated GluR1 translation. The results demonstrate the practicality of this assay to explore the contribution of RARα to this pathway and that the capacity of RAR ligands to activate translation is a quality restricted to a limited number of compounds, with implications for their RAR selectivity and potentially their specificity in drug use.

Keywords RAR · Retinoic acid · GluR1 · Non-genomic

Introduction
Nuclear receptors are involved in a major set of signalling pathways in the brain, and crucial among these is the retinoic acid receptor (RAR) family [1]. They have a well described mechanism of action to regulate gene expression [2]. In addition, “non-genomic” roles have been described for these receptors and a vital action for retinoic acid receptor alpha (RARα) in the brain is regulation of mRNA translation during homeostatic synaptic plasticity [3].

Synaptic connections in the brain are highly plastic. The number and strength of synapses in neural pathways can be modified in response to different factors such as experience and this is an important element in the formation of memory. With changes in synaptic strength, however, it is important to maintain the stability of neural networks in order to prevent the neural circuits from becoming hyper- or hypo-active [4, 5]. The ability of neurons to adjust their activity levels and maintain a balance between the relative strength of individual synapses is called homeostatic synaptic plasticity [6, 7]. Homeostatic synaptic plasticity adjusts total synaptic strength through different mechanisms such as regulating the release and/or reuptake of presynaptic transmitters and changing the number and/or sensitivity of postsynaptic receptors in order to maintain a balance [8, 9]. For example, pharmacological manipulation studies have shown that an increase in synaptic strength is induced when neural activity is inhibited by tetrodotoxin (TTX; which blocks sodium-gated voltage channels) and an N-methyl-D-aspartate receptor (NMDA) receptor antagonist [10, 11]. This synaptic increase in neural activity is mediated by an increase in local translation and insertion of the glutamate receptor 1 (GluR1, also known as GRIA1 and GluA1) subunits of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor [12–14]. AMPA
receptors are glutamate excitatory transmembrane receptors that mediate most of the neuroexcitatory synaptic transmission in the central nervous system. AMPA receptors are composed of four subunits (GluR1-GluR4), and they mediate neuromodulation and play an important role in cognition, memory, and learning [15].

Retinoic acid (RA) is synthesised in neurons in response to a decrease in neural activity. Aoto and colleagues demonstrated that the application of RA to hippocampal cultures increased the amplitude of spontaneous excitatory postsynaptic currents and that activity blockade induced RA synthesis in the neurons [16–18]. The synthesised RA mediated a type of homeostatic plasticity by regulating the translation of the GluR1 subunit of the AMPA receptor in postsynaptic membranes [3]. It does this through a cytoplasmically localised population of the nuclear receptor RARα [16]. In the absence of RA, the F-domain of RARα binds directly to consensus sequences in the 5′ untranslated region (5′ UTR) of GluR1 mRNA; this is thought to inhibit the scanning mechanism, whereby the 43S pre-initiation complex searches for the initiation codon to start translation. During synaptic scaling, blockade of synaptic activity triggers RA synthesis and the RA binds to RARα. The ligand binding domain of RARα undergoes a conformational change shifting position of helix 12, and it is proposed also the adjacent F-domain [3], resulting in the weakening of the affinity for mRNA; and so the GluR1 mRNA is released allowing it to be translated. This causes an increase in the postsynaptic AMPA receptor levels [3, 16].

In the current study, we wanted to design a simple quantitative system that detects the effects of RA analogues on post-transcriptional gene regulation in neurons during synaptic scaling, in order to study factors that can promote or inhibit this regulatory system. A bioluminescence reporter plasmid scaling, in order to study factors that can promote or inhibit transcriptional gene regulation in neurons during synaptic scaling, in order to study factors that can promote or inhibit this regulatory system. A bioluminescence reporter plasmid

**Materials and Methods**

**Retinoids**

All-trans RA (ATRA) was purchased from Sigma-Aldrich. HX600 and DA124 were a gift from Dr. Kagechika (Tokyo). Synthetic retinoids and some non-retinoid homologues were designed and prepared by the Whiting group (Durham University) as described previously [20–24]. The molecular structure of the RAR and RXR ligands used is shown in Fig. 1.

**Construction of Plasmids for GluR1 Assay**

Firefly luciferase GluR1 reporter plasmid pTK1 was built from a pGL3 (R2.1) vector (Promega) derivative that expresses luciferase destabilised by addition of a PEST motif under the control of a simian virus 40 (SV40) early promoter and is referred to here as pGL3 (R2.1) promoter.

To generate pTK1, a 309-bp 5′ UTR fragment of the rat GluR1 gene was generated by PCR from genomic DNA prepared from rat HCN-A94 neural stem cells, using the Expand™ High Fidelity PCR System kit (Sigma-Aldrich) and primers AGGAGAGCAGAGGGAGAGG and CAAAGAGTGACGCGATATCCTT. Fifteen base-pair extensions homologous to the vector ends were added by PCR using nested primers CTTTTGCAAATACCTTGCTC GGCTCCCTCTTCC and TTGGCGTCTTCCATGGAGAT TTGGTCTTCTCCCTCCC. The resulting PCR products were then inserted into HindIII/NcoI cut pGL3 (R2.1) promoter vector using the In-Fusion® HD Cloning Kit (Clontech) to generate GluR1 recombinant plasmid pTK1 containing the rat GluR1 5′ UTR. The sequence was confirmed by Sanger sequencing performed at the Dundee University DNA sequencing service.

**CRISPR/CAS9 Plasmid Construction for Knockout of RARα**

The Gibson Designer tool at the Wellcome Trust Sanger Institute Genome Editing database (WGE) [25] was used to identify exon 7 as a target for disruption of the human RARα open reading frame (ORF). Exon 7 was chosen because it is present in all transcripts, and removing it causes frameshift mutations leading to premature termination codons that make the RNA subject to nonsense-mediated decay. Guide sequences in RARα exon 7 were identified using the CRISPR Finder tool in WGE. Oligonucleotides ACACGCCCGT ACACGCCCGAGC and GCTCGGGCGTGTACCGCGTG were annealed in CutSmart® Buffer (NEB) and cloned into the BbsI cut pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene 42,230) using Instant Sticky-end Ligase Master Mix (NEB) to produce pTK3.

A homologous direct repair (HDR) donor plasmid was prepared in order to introduce a puromycin cassette to repair the DNA double-strand break generated by Cas9 nuclease in RARα exon 7. The plasmid contains a puromycin selection marker flanked by 1253 and 1313 base pairs of genomic DNA from upstream and downstream of RARα exon 7. These
fragments were amplified from genomic SH-SY5Y DNA using primers CATGTGAGGCAAGAGATAAGTCAAC and CTGAACCCGAACCCACTCTGAG, and TCTGTTAGGTATCTCTAGAGGGCAG and GCATCTTTCTTGGGATTCAGTTCTT, respectively, using Phusion® High-Fidelity DNA Polymerase (NEB). Further PCR reactions were then carried out to add extension to the 5′ and 3′ flanks of the PCR products that were homologous to the vector ends using primers AAACGACGGCCAGTGAATTCCATGTGAGGCAAGAGATAAGTCAAC and GCCGTTTGGTGATTCCTGAAGTCCCTGAACCCGAACCCACTCTGAG, and TATCATGTCTGGATCCGGGGTCTGTTAGGTATCTCTAGAGGGCAG and CCATGATTACGCCAAGCTTGATGCATCTTTCTTGGGATTCAGTTCTT, respectively. The puromycin cassette was amplified from SERP_100_puc19_GIBSON_EF1a_PURO plasmid (a gift from Dr. Bill Skarnes, Wellcome Trust Sanger Institute) using primers GGAACTTCGAACCCGACGGC and CCCCGGATCCAGACATGATA. The plasmid backbone was obtained by digesting SERP_100_puc19_GIBSON_EF1a_PURO plasmid with EcoRI/ HindIII enzymes. The four overlapping DNA fragments were joined together to produce pTK4 using the Gibson Assembly® Cloning Kit (NEB) according to the manufacturer’s recommendations.

**Cell Lines and Cell Culture Conditions**

SH-SY5Y cells [26] were grown in T-75 culture flasks in DMEM (Thermo Fisher Scientific) containing 10% FCS (Thermo Fisher Scientific) and at 5% CO₂/37 °C. SH-SY5Y cells (SH-SY5Y RARα) in which human RARα cDNA was conditionally over-expressed in response to tetracycline were supplied by Dr. Danielle Lindley [27]. These cells had been prepared by stable transfection of human RARα2 cDNA
Preparation of RARα± Hemizygous Knockout SH-SY5Y Line

SH-SY5Y cells were plated in 6-well plates at a density of 1.2 × 10^6 cells per well in 1-ml media and left to attach overnight in DMEM medium containing 10% FCS. Cells were then transfected with 1.5 µg of pTK3 and pTK4 plasmids each using jetPRIME® transfection reagent (Polyplus-transfection SA) according to the manufacturer’s recommendation. Cells were then incubated for 4 h in a 5% CO₂/37 °C incubator before exchanging with normal DMEM containing 10% FCS without puromycin antibiotic. The next day, the medium was replaced with DMEM with 10% FCS and containing 2.5 µg/ml puromycin for selection. The medium was changed every 3 days for a 10-day period.

Single SH-SY5Y colonies were picked and grown to confluency in wells of a 24-well plate containing 500 µl of DMEM with 10% FCS and 2.5 µg/ml puromycin. The cells in each well were then split and some of them were used for DNA analysis while the rest were grown for cryopreservation.

DNA was extracted from SH-SY5Y cells using an ISOLATE genomic DNA mini Kit (Bioline) according to the manufacturer’s instructions. PCR reactions were carried out to confirm RARα gene disruption using a GoTaq G2 polymerase (Promega) to analyse the RARα gene using five different pairs of primers.

The location of primer pairs used to characterise the knockout cell lines is shown in Fig. 2. Primer pair 1 (TGCAACCAC CATCCCTCTCCT and CGAGGTGGGAAGATCAATAC TGCT) binds upstream and downstream of the region used for gene disruption (exon 7 deletion) and normally produces a 2.9-kbp product. Insertion of the puromycin cassette increases the length of this amplicon to 5.4 kbp. Primer pairs 2 (TGCAACCACATCCCTCTCCT and CGGAAGGCCAGTTG) and 4 (TCAGCGCATCTGCTCCTAT and CGAGGTGGGAAGATCAATACTGCT) both detect the presence of exon 7, and both produce amplicons of 1.4 kbp. Insertion of the puromycin cassette at this locus is detected by primer pairs 3 (TGCAACCACATCCCTCTCCT and GCATGCTTTTCTCCACCTCAGT) and 5 (CTTCACCCTCACCGCGAGTGAGAGTATCAGTAC TGCT) and they produce amplicons of 1.5 kbp and 1.8 kbp, respectively.

GluR1 Translation Assay

SH-SY5Y cells were seeded in 24-well plates at a density of 20,000 cells per well in 500 µl DMEM containing 10% FCS without antibiotics. SH-SY5Y cells were then transfected with one of the recombinant reporter plasmids pTK1 using jetPRIME® transfection reagent. In parallel, cells were transfected with two control plasmids pGL3 (R2.1) promoter and the pGL3-Basic plasmid (Promega, GenBank U47295) without promoter. In addition, each recombinant/control plasmid was co-transfected with a plasmid expressing Renilla luciferase (pRL-TK; Promega; GenBank AF025846.2) used as an internal transfection control. The transfection mixtures were prepared using 600 ng of recombinant/control firefly plasmid and 150 ng of Renilla luciferase plasmid pRL-TK and added to cells according to the manufacturer’s recommendation.

Twenty-four hour after transfection, the medium was replaced with normal culture medium containing the test retinoid or DMSO alone as a standard. Retinoid dilutions were prepared in DMEM with 10% FCS from stock solutions in DMSO. Each retinoid was tested in triplicate at 10 µM concentration with a final DMSO concentration of 0.1%. In the case of SH-SY5VRARα± cells, the cells were also treated with doxycycline (Melford) at a concentration of 1 µg/ml along with the retinoids to drive RARα overexpression.

Dual Luciferase Assay

Firefly and Renilla luciferases were measured sequentially using the Dual-Luciferase reporter assay system (Promega) according to the manufacturer’s protocol. After 24 h of retinoid treatment, the medium was removed and the cells were washed with 250 µl of PBS; 100 µl of passive lysis buffer was then added to each well, and the plates incubated on a plate shaker at room temperature for 15 min. Cell lysates (10 µl) were transferred into wells of a 96-well white luminometer plate (Greiner Bio-One), and the luciferase assays were performed using a GloMax® 96 Microplate Luminometer (Promega) according to the manufacturer’s protocol.

Protein Analysis and Western Blotting

Cells were washed with cold PBS and lysed with 150 mM NaCl, 1% Triton, 0.1% SDS, 50 mM HEPES containing protease inhibitor cocktail (Sigma) in double-distilled water. Protein concentrations were measured using a BCA assay kit (Thermo Fisher Scientific). Fifty micrograms of protein was...
loaded and separated by electrophoresis through 12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Rabbit anti-RARα primary antibody (Santa cruz, sc-551) along with horseradish peroxidase-conjugated secondary anti rabbit IgG antibody (Jackson Immunoresearch) and anti-β-actin peroxidase mouse primary antibody (Sigma, A3854) were used in the study. Western blots were developed using enhanced chemiluminescence (Millipore), and the protein bands were detected and scanned using a myECL Imager (ThermoScientific).

**Statistical Analysis**

All data are presented as mean ± SEM of three independent experiments. Statistical analyses were performed in Microsoft Office Excel 2017, GraphPad Prism 7.0c version (Prism, GraphPad Software, San Diego, CA) or R version 3.3.1 (R Core Team, Vienna, Austria: The R Foundation for Statistical Computing). The data were analysed by Student’s t test, one-way ANOVA with Newman-Keuls multiple comparison test, or linear models with RARα expression level as an ordered
factor, as appropriate; a $p$ value $< 0.05$ was considered statistically significant. $^* p \leq 0.05$, $^* * p \leq 0.01$, $^* * * p \leq 0.001$, $^* * * * p \leq 0.0001$.

**Results**

**A Dual Luciferase Assay for Detecting RARα-Ligand Regulation of GluR1 Translation**

To quantify RARα ligand regulation of GluR1 translation, a highly sensitive bioluminescence reporter composed of firefly luciferase under the control of the GluR1 5′ UTR was employed. The rat GluR1 5′ UTR sequence was chosen based on previous work by Poon and Chen who identified consensus RNA binding motifs in the 5′ UTR regions of rat GluR1 mRNA that preferentially bind RARα for translational control [3]. This region including the RARα binding motifs is conserved in the human GluR1 5′ UTR (Fig. 3a). Based on that, a firefly luciferase GluR1 reporter plasmid, designated pTK1, was designed by cloning a fragment of the 5′ UTR region (that contains consensus motifs) from rat GluR1 into a pG3 (R2.1) under control of the SV40 promoter. Figure 3 b shows the sequence of the relevant regions of pTK1 construct.

The construct was transfected into SH-SY5Y cells, a frequently used model of neuronal cells, employing a SH-SY5YRARα variant in which high levels of RARα expression can be induced with tetracycline or the more stable derivative doxycycline [30]. SH-SY5YRARα cells were transfected with the rat GluR1 reporter pTK1, or a pG3 (R2.1) promoter parental plasmid lacking the insert to demonstrate that the response is due to the sequence inserted. In addition, the pG3-Basic-plasmid, lacking a promoter but containing a normal firefly luciferase gene without the destabilising PEST sequence present in the pG3 (R2.1) derivatives, was used as a sensitive control for promoter and GluR1 5′ UTR-independent effects of RARα on luciferase expression. For all assays, cells were co-transfected with pRL-TK expressing Renilla luciferase as reference and independent measure of transfection efficiency. Transfected cells were treated with 10-μM ATRA for 24 h, and then luciferase activities were measured (Fig. 4). Ten μM ATRA was used because in many studies SH-SY5Y cells are treated with this concentration of ATRA in order to study its action [31–34].

In a first experiment, the effect of ATRA on reporter gene expression was analysed in SH-SY5YRARα cells grown in the absence of doxycycline, and so without RARα overexpression (Fig. 4a). Firefly and Renilla luciferase activities were measured separately, and for comparison, firefly luciferase activity was normalised with respect to Renilla luciferase activity and standardised with respect to activity in cells not treated with ATRA. In the case of the two controls, pG3-Basic and pG2 (R2.1) promoter, luciferase activity did not significantly differ between cells treated with/without ATRA. On the other hand, cells transfected with pTK1 containing the rat GluR1 5′ UTR showed an approximately 1.6-fold increase in luciferase expression when treated with ATRA. These results indicate that the reporter assay was, as expected, responsive to RA.

The effect of RARα overexpression was tested by inducing RARα expression with doxycycline. Overexpression of RARα had no significant effect on the response to ATRA of the different plasmids used as negative controls: only luciferase under the control of the rat GluR1 5′ UTR region was increased by treatment with ATRA (Fig. 4b). However, given that the response to ATRA was significantly less following doxycycline-induced RARα over-expression ($p = 0.0231$), routine assays were done without doxycycline-treatment of SH-SY5YRARα cells.

**The Luciferase Assay Is Sensitive to RARα Levels**

Our assay models the effects of RARα in controlling translation of GluR1 mRNA. To test whether the response was showing the SV40 promoter shaded in yellow, the GluR1 5′ UTR shaded in blue, and the beginning of the firefly luciferase open reading frame in green. The RARα consensus binding sites are in red and underlined, while vector sequence is unshaded.

---

**Fig. 3** Retinoic acid control of GluR1 translation. a Alignment of 5′ UTR sequences of human and GluR1 mRNA. The RARα consensus binding sites identified previously by Poon and Chen using SELEX are underlined and in bold. b Partial sequence of the pTK1 construct
sensitive to RARα levels, we directly compared the response to ATRA in SH-SY5Y hemizygous RARα± knockout cells to parental SH-SY5Y cells and SH-SY5Y RARα cells overexpressing RARα after 1 µg doxycycline treatment. Analysis by Western blotting demonstrated clear differences in RARα protein levels in these three cell types (Fig. 5a), with a 2.5-fold higher RARα level in the doxycycline-treated SH-SY5Y RARα cell line and a 2.1-fold lower RARα level in the hemizygous RARα± SH-SY5Y cell line compared to the parental SH-SY5Y cells.

The three different cell types were then transfected with pTK1 and pRL-TK and treated with/without ATRA to determine the effects of RARα levels on the reporter assay (Fig. 5b). There was a clear reduction in reporter activity (effect coefficient −0.8) as RARα expression levels increased (Linear model with RARα expression as an ordered factor: \( p < 0.001 \); Fig. 5b), and ATRA treatment had a clear effect in inducing a 2.3- to 2.6-fold increase in reporter activity (Linear model, effect of RA, \( p < 0.001 \)). In addition, ATRA treatment had a significant effect (Linear model, interaction term, \( p = 0.04 \)) in increasing the negative relationship between RARα expression levels and reporter activity. These results show that the effect of RARα is dose-dependent, with the lowest reporter activity in cells with the highest RARα expression (Fig. 5b).

Having established that pTK1 containing the rat GluR1 5′ UTR region was, as expected, responsive to RA, we exploited this to screen novel synthetic RAR and two commercially available RXR ligands with differing capacity to induce ligand-activated transcription (unpublished data), for their ability to regulate GluR1 translation compared to ATRA. TTNN, AH61, DC271, DC440 and DC444 are analogues of ATRA that exhibit strong binding affinity for the RARs, while DC303, DC324 and DC329 are non-active retinoid analogues that were designed specifically to be longer structures than RA and would therefore be unable to bind into the RAR ligand-binding pocket [21, 35, 36]. HX600 [37] and DA124 [38] are known to be RXR agonists that do not exhibit significant binding affinity for the RARs. SH-SY5Y RARα cells cotransfected with pTK1 containing the rat GluR1 5′ UTR region, and pRL-TK expressing Renilla luciferase were treated for 24 h with 10 µM retinoids, and for comparison with 10 µM ATRA or with the solvent DMSO (Fig. 6). In addition to ATRA, treatment with only four out of the tested RAR or RXR ligands, namely TTNN, AH61, DC271 and DC440 caused a statistically significant increase in luciferase activity. In addition, treatment with DC444 also increased luciferase activity, but not significantly. DA124 and HX600 did not have any effect on luciferase activity as expected because they are RXR, and not RAR, ligands.

Discussion

A sensitive bioluminescence-based dual luciferase assay was developed to enable the study of the translational control of GluR1 mRNA by RARα. For this assay, the 5′ UTR region of
rat GluR1 gene was inserted upstream of the initiation codon of a luciferase gene. Using this construct, together with pRL-TK expressing Renilla luciferase as reference and in combination with SH-SY5Y cells with normal, elevated or reduced RARα levels, the effect of RARα levels, and of synthetic RAR/RXR ligands, could be quantified for their capacity to regulate GluR1 translation by measuring changes in luciferase activity.

Control of translation by RA via RARα is a non-genomic activity, breaking the dogmatic view of the RARs as purely transcriptional regulators restricted to the nucleus [3, 16, 39]. RARα is actively exported from the nucleus by a nuclear export signal (NES) present in domain E (the ligand binding domain) of the receptor [3, 40]. In the cytoplasm, RARα acts as an RNA binding protein, binding directly to different mRNAs such as dendritically localised GluR1 mRNA. The C-terminal F-domain of RARα binds to specific sequences in the 5’UTR region of the rat GluR1 mRNA and represses the translation of GluR1 [3]. This mechanism of inhibition may be similar to the translational control of ferritin mRNA by iron regulatory protein (IRP), which binds to the ferritin mRNA and prevents the binding of the 43S pre-initiation complex to it [41]. RA binding to RARα causes conformational changes in the receptor which relieves the association between RARα and GluR1 mRNA, resulting in GluR1 translation [3]. Schwertz and colleagues also showed that RARα can regulate mRNA translation via interaction with the 3’UTR of genes, as well as their 5’UTR region [42]. They reported in human platelets the presence of the RARα consensus binding sites identified previously by Poon and Chen [3] in the 3’UTR region of microtubule associated protein 1 light chain 3 beta 2 (MAP1LC3B2) transcripts, the 3’UTR and 5’UTR regions of SLAIN motif containing protein 2 (SLAIN2) and the 5’UTR region of angiopoietin-1 (ANGPT1) [42]. Thus RA can regulate translation of several proteins [42] but GluR1 is the only regulated subunit presently described to be part of an ionotropic receptor.

Notably, this study demonstrated that RARα is involved in GluR1 translation as reported previously [3, 16, 39] by demonstrating a negative dose-dependent effect of RARα on the
GluR1 translation assay (Fig. 5). However, we could not con-
firm whether RARα is the only receptor regulating GluR1 in
response to RA, as we were unable to test cells lacking all
RARα genes.

An ATRA concentration of 10 μM was used in this assay.
Almost all studies treating SH-SY5Y cells with ATRA use a
high, 10 μM concentration, for example [31–34]. The most
effective concentration for inducing differentiation of SH-
SY5Y cells using ATRA is 10 μM concentration [43, 44],
which may be because ATRA rapidly induces strong expres-
sion of the catabolic enzymes CYP26A1 and CYP26B1 [45],
which counteract the effects of RA, thus necessitating high
concentrations.

A range of RAR ligands together with two known RXR
ligands were tested for their capacity to regulate GluR1 trans-
laction (Fig. 6). Of those tested, only four increased
GluR1 translation significantly, i.e. DC271, DC440,
TTNN and AH61 with DC271 and DC440 also being
stronger than ATRA, although not significantly. As ex-
pected, neither of the RXR ligands, DA124 nor HX600
increased GluR1 translation. Thus, it is the synthetic
retinoids that activate RARs, and not those that only
activate RXRs, which induce GluR1 translation. The
use of the dual luciferase GluR1 translation assay to
screen for bioactive compounds that promote GluR1
translation will identify routes by which homeostatic plasticity
in the brain may be promoted. This may be of application to
disorders such as fragile X syndrome in which homeostatic
plasticity is impaired which may contribute to the neural dys-
fuction in this disease [46].

In summary, a reporter gene system has been developed to
study the translational control of GluR1 by RA. The assay was
used to investigate the influence of levels of RARα expression
on GluR1 translation. This approach can be used to investigate
any protein that influences this pathway as proposed for frag-
ile X mental retardation protein (FMRP) [46]. Exploration of
the system may show a level of control parallel to the enor-
mous complexity of RAR regulated transcription and the
dozens of coregulators that contribute to this. This assay can
also be used to identify RARα ligands for their capacity to
increase GluR1 expression which will then increase AMPA
receptor levels and which may provide therapeutics that reg-
ulate homeostatic plasticity in the brain. The insights demon-
strated here could potentially be used to design RAR ligands
of greater specificity for RAR triggered pathways, allowing
the development of RAR-based therapeutics with fewer side
effects for disorders impacted on by neuroplasticity, such as
Alzheimer’s disease [47].

Funding Information This study received support from BBSRC
grant BB/P004806/1.

Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give approp-
riate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References

1. Ana Maria A, Oscar Andřes M-R, Haider NB (2016) Role of nuclear receptors in central nervous system development and associated diseases. J Exp Neurosci 9:93–121. https://doi.org/10.14317/JEN.252480

2. Aranda A, Pascual A (2001) Nuclear hormone receptors and gene expression. Physiol Rev 81:1269–1304. https://doi.org/10.1152/physrev.2001.81.3.1269

3. Poon MM, Chen L (2008) Retinoic acid-gated sequence-specific translational control by RAR. Proc Natl Acad Sci 105:20303–20308. https://doi.org/10.1073/pnas.0807740105

4. Turrigiano GG, Nelson SB (2004) Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 5:97–107. https://doi.org/10.1038/nrn1327

5. Abbott LF, Nelson SB (2000) Synaptic plasticity: taming the beast. Annu Rev Neurosci 23:351–388. https://doi.org/10.1146/annurev.neuro.23.1.351

6. Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB (2002) Synaptic gain control and homeostasis. Curr Opin Neurobiol 13:560–567. https://doi.org/10.1016/j.conb.2003.09.007

7. Burrone J, Murthy VN (2003) Synaptic gain control and homeostasis. Curr Opin Neurobiol 13:560–567. https://doi.org/10.1016/j.conb.2003.09.007

8. Davis GW (2006) Homeostatic control of neural activity: from phenomenology to molecular design. Annu Rev Neurosci 29:307–323. https://doi.org/10.1146/annurev.neuro.28.061004.135751

9. Turrigiano G (2012) Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function. Cold Spring Harb Perspect Biol 4:1–17. https://doi.org/10.1101/cshperspect.a005736

10. Lison DV, Gomperts SN, Carroll RC, Christine CW, Kalman D, Kitamura M, Hardy S, Nicoll RA et al (1998) Activity-differentiation regulates the surface expression of synaptic AMPA and NMDA glutamate receptors. Proc Natl Acad Sci U S A 95:7097–7102. https://doi.org/10.1073/pnas.95.12.7097

11. Watt AJ, Van Rossum MCW, MacLeod KM et al (2000) Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron 26:659–670. https://doi.org/10.1016/S0896-6273(00)81202-7

12. Ju W, Morishita W, Tsui J, Giaietta G, Deerinck TJ, Adams SR, Garner CC, Tien SY et al (2004) Activity-dependent regulation of dendritic synthesis and trafficking of AMPA receptors. Nat Neurosci 7:244–253. https://doi.org/10.1038/nn1189

13. Sutton MA, Ito HT, Cressy P, Kempf C, Woo JC, Schuman EM (2004) Regulation of dendritic protein synthesis by miniature synaptic events. Science 307:7102. https://doi.org/10.1126/science.1108526

14. Sutton MA, Wall NR, Aakalu GN, Schuman EM (2004) Activity-dependent scaling of quantal amplitude in neocortical neurons. Curr Opin Neurobiol 14:233–240. https://doi.org/10.1016/j.conb.2004.02.002

15. Hodgkins A, Fame A, Perera S, Gregg T, Parry-Smith DJ, Skarnes WC, Iyer V (2015) WGE: a CRISPR database for genome engineering. Bioinformatics 31:3078–3080. https://doi.org/10.1093/bioinformatics/btv308

16. Turrigiano GG, Nelson SB (2004) Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 5:1–10. https://doi.org/10.1038/nrn1327

17. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1993) Transcriptional activation by tetracyclines in mammalian cells. Science (80- ) 268:1766–1769. https://doi.org/10.1126/science.81453

18. Gottschalka D, Collings JC, Maltman DJ, Redfern CPF (2008) Retinoids and cell signalling. Biochemical Society Transactions 36:578. https://doi.org/10.1042/bst036578

19. Forster JL, Köglsberger S, Trefoi C, Boyd O, Baumuratov AS, Kimura K, Bujard H (2013) The molecular basis of the interactions between synthetic retinoic acid analogues and the retinoic acid receptors. Med Chem Comm 8:578–592. https://doi.org/10.1039/C6MD00680A

20. Dunn S, Durack E, Kiely PA (2013) Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration. BMC Res Notes 6:366. https://doi.org/10.1186/1756-2890-6-366

21. Nicolini G, Miloso M, Zovio C, di Silvestro A, Cavaletti G, Tredici G (1998) Retinoic acid differentiated SH-SY5Y human neuroblastoma cells: an in vitro model to assess drug neurotoxicity. Anticancer Res 18:2477–2481
35. Gluyas JBG, Burschka C, Dörrich S, Vallet J, Gronemeyer H, Tacke R (2012) Disila-analogues of the synthetic retinoids EC23 and TTNN: synthesis, structure and biological evaluation. Org Biomol Chem 10:6914–6929. https://doi.org/10.1039/c2ob25989c
36. Whiting A, Marder T (2014) Fluorescent synthetic retinoids. UK patent application no. GB1417957.6, 2014.
37. Morita K, Kawana K, Sodeyama M, Shimomura I, Kagechika H, Makishima M (2005) Selective allosteric ligand activation of the retinoid X receptor heterodimers of NGFI-B and Nurr1. Biochem Pharmacol 71:98–107. https://doi.org/10.1016/j.bcp.2005.10.017
38. Ohta K, Tsuji M, Kawachi E et al (1998) Potent retinoid synergists with a diphenylamine skeleton. Biol Pharm Bull 21:544–546. https://doi.org/10.1248/bpb.21.544
39. Maghsoudi B, Poon MM, Nam CI, Aoto J, Ting P, Chen L (2008) Retinoic acid regulates RARalpha-mediated control of translation in dendritic RNA granules during homeostatic synaptic plasticity. Proc Natl Acad Sci U S A 105:16015–16020. https://doi.org/10.1073/pnas.0804801105
40. Huang H, Wei H, Zhang X, Chen K, Li Y, Qu P, Zhang X, Chen J et al (2008) Changes in the expression and subcellular localization of RARα in the rat hippocampus during postnatal development. Brain Res 1227:26–33. https://doi.org/10.1016/j.brainres.2008.06.073
41. Gray NK, Hentze MW (1994) Iron regulatory protein prevents binding of the 43S translation pre-initiation complex to ferritin and eALAS mRNAs. EMBO J 13:3882–3891
42. Schwertz H, Rowley JW, Zimmerman GA, Weyrich AS, Rondina MT (2017) Retinoic acid receptor-α regulates synthetic events in human platelets. J Thromb Haemost 15:2408–2418. https://doi.org/10.1111/jth.13861
43. Shipley MM, Mangold CA, Szpara ML (2016) Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis Exp:1–11. https://doi.org/10.3791/53193
44. Encinas M, Iglesias M, Liu Y, Wang H, Muhsain A, Ceña V, Gallego C, Comella JX (2002) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 75:991–1003. https://doi.org/10.1046/j.1471-4159.2000.0750991.x
45. Stoney PN, Fragoso YD, Saeed RB, Ashton A, Goodman T, Simons C, Gomaa MS, Sementilli A et al (2016) Expression of the retinoic acid catabolic enzyme CYP26B1 in the human brain to maintain signaling homeostasis. Brain Struct Funct 221:3315–3326. https://doi.org/10.1007/s00429-015-1102-z
46. Zhang Z, Marro SG, Zhang Y, Arendt KL, Patzke C, Zhou B, Fair T, Yang N et al (2018) The fragile X mutation impairs homeostatic plasticity in human neurons by blocking synaptic retinoic acid signaling. Sci Transl Med 10:eaar4338. https://doi.org/10.1126/scitranslmed.aar4338
47. Chang PKY, Verbich D, Mckinney RA (2012) AMPA receptors as drug targets in neurological disease - advantages, caveats, and future outlook. Eur J Neurosci 35:1908–1916. https://doi.org/10.1111/j.1460-9582.2012.08165.x

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.